510(k) Report

510(k) · Cleared

Cleared

Transpara

K181704510(k) TraditionalCleared Nov 21, 2018147-day reviewClass II21 CFR 892.2090

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Screenpoint Medical B.V. · QDQ Radiological Computer Assisted Detection/Diagnosis Software For Lesions Suspicious For Cancer

Cleared on Nov 21, 2018 as substantially equivalent to DEN180005 (Imagen Technologies, Inc., 2018) after a 147-day review. Its family tree reaches back 1 generation to 2018. 32 later devices descend from it.

Decided
Nov 21, 2018
Review
147 days
Class
Class II
Product code
QDQ
Recalls
None
Predicates
1

Its longest line of descent runs back 1 generation to DEN180005 (2018). 32 later devices descend from it, 6 citing it directly.

Descendants, by year cleared 2020: 2 descendants cleared2025: 4 descendants cleared2019: 1 descendant cleared2022: 3 descendants cleared2021: 4 descendants cleared2024: 6 descendants cleared2026: 10 descendants cleared2023: 2 descendants clearedDEN180005 · OsteoDetect · Imagen Technologies, Inc. · 2018201620182020202220242026
Descendants, by generation 1 generation forward: 6 descendants2 generations forward: 8 descendants3 generations forward: 7 descendants4 generations forward: 5 descendants5 generations forward: 6 descendants DEN180005 · OsteoDetect · Imagen Technologies, Inc. · 20180+5
  1. Root · 1 generation backDEN180005 OsteoDetectImagen Technologies, Inc. · 2018
  2. This deviceK181704 TransparaScreenpoint Medical B.V. · 2018
  3. Descendant · cites it directly · 9 of its ownK193229 TransparaScreenpoint Medical B.V. · 2020
  4. Descendant · cites it directly · 6 of its ownK192287 TransparaScreenpoint Medical B.V. · 2019
  5. Descendant · 2 generations on · 5 of its ownK211678 Lunit INSIGHT MMGLunit, Inc. · 2021
  6. Descendant · 2 generations on · 5 of its ownK210404 Transpara 1.7.0Screenpoint Medical B.V. · 2021
  7. Descendant · 3 generations on · 4 of its ownK221347 Transpara 1.7.2Screenpoint Medical B.V. · 2022

Showing 5 of 32 descendants. See all descendants

Descendants cleared per year

2019: 12020: 22021: 42022: 32023: 22024: 62025: 42026: 10
2019high 10 (2026) · low 1 (2019)2026

Most influential descendants

Showing 5 of 32 · See all
  • K193229TransparaScreenpoint Medical B.V. · 2020 · cites it directly9descendants
  • K192287TransparaScreenpoint Medical B.V. · 2019 · cites it directly6descendants
  • K211678Lunit INSIGHT MMGLunit, Inc. · 2021 · 2 generations on5descendants
  • K210404Transpara 1.7.0Screenpoint Medical B.V. · 2021 · 2 generations on5descendants
  • K221347Transpara 1.7.2Screenpoint Medical B.V. · 2022 · 3 generations on4descendants
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
−1DEN180005OsteoDetectImagen Technologies, Inc.2018—
0 (this device)K181704TransparaScreenpoint Medical B.V.2018—
+1K193229TransparaScreenpoint Medical B.V.2020—
+1K192287TransparaScreenpoint Medical B.V.2019—
+2K211678Lunit INSIGHT MMGLunit, Inc.2021—
+2K210404Transpara 1.7.0Screenpoint Medical B.V.2021—
+3K221347Transpara 1.7.2Screenpoint Medical B.V.2022—

Descendants by year cleared

Year clearedDevicesWith a Class I recall
201910
202020
202140
202230
202320
202460
202540
2026100
FIG. 1 — Lineage of K181704, 2018–2026Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in QDQ? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new QDQ device

  1. #1 K241831 Transpara (2.1.0)score 15.6 · 5 generations · no Class I recall
  2. #2 Held for the reportin the report
  3. #3 Held for the reportin the report
Get a 510(k) Report

What was it cleared against? (1)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*DEN180005OsteoDetect
Summary page 7
…isk 5-40 Management To Medical Devices IEC 62304:2015 Medical Device Software - Software Life 13-79 Cycle Processes DEN180005 Evaluation of automatic class III N/A designation for OsteoDetect – Decision…
Imagen Technologies, Inc.2018—

Also cleared against DEN180005: 3 other devices →

What descends from it? (32)

See all 32

6 later devices cite it directly; ranked here by how many devices descend from each in turn.

NumberDeviceApplicantDecidedDescendants
K193229TransparaScreenpoint Medical B.V.20209
K192287TransparaScreenpoint Medical B.V.20196
K220105Saige-DxDeepHealth, Inc.20224
K192854MammoScreenTherapixel20204
K210670BU-CADTaihao Medical, Inc.20213
K241770Prostate MR AI (VA10A)Siemens Healthcare GmbH20250

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • Its one ancestor has no recall.
  • Of its descendants, K193229 (Screenpoint Medical B.V., 2020) has gone furthest, with 9 descendants of its own.
  • 3 other devices also cite its predicate DEN180005.

How does its category compare?

All QDQ devices

QDQ Radiological Computer Assisted Detection/Diagnosis Software For Lesions Suspicious For Cancer: FDA decisions, review times, recalls and adverse event reports over 20 years. 2018, this device’s year, is highlighted.

FDA decisions per year · QDQ

10so far in 2026, the most since 2007

2018: 22019: 22020: 32021: 52022: 42023: 22024: 72025: 52026 (partial year): 10
2007high 10 (2026) · low 0 (2007)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · QDQ

216in 2025

2020: 173 days median2021: 169 days median2022: 131 days median2024: 153 days median2025: 216 days median2026 (partial year): 154 days median
2007high 216 (2025) · low 131 (2022)2026

Receipt to decision; years with fewer than 3 clearances left blank.

Recalls per year · QDQ

No recall names QDQ since 2007.

Adverse event reports per year · QDQ

No MAUDE report names QDQ since 2007.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20070—00
20080—00
20090—00
20100—00
20110—00
20120—00
20130—00
20140—00
20150—00
20160—00
20170—00
20182—00
20192—00
2020317300
2021516900
2022413100
20232—00
2024715300
2025521600
2026101540—

What is it indicated for?

The ScreenPoint Transpara™ system is intended for use as a concurrent reading aid for physicians interpreting screening mammograms, to identify regions suspicious for breast cancer and assess their likelihood of malignancy. Output of the device includes marks placed on suspicious soft tissue lesions and suspicious calcifications; region‐based scores, displayed upon the physician’s query, indicating the likelihood that cancer is present in specific regions; and an overall score indicating the likelihood that cancer is present on the mammogram. Patient management decisions should not be made solely on the basis of analysis by Transpara™.

Indications for use as stated in the FDA summary.

Cite this page

510(k) Report. “K181704: Transpara.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K181704

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026